Disappointing results in a Phase III clinical trial of Dimebon in Alzheimer’s Disease (AD)
نویسنده
چکیده
The Alzheimer’s trial, called CONNECTION, was a multi-national, double-blind, placebo-controlled safety and efficacy trial involving 598 patients with mild-to-moderate AD at 63 sites in North America, Europe, and South America. Patients were randomly assigned to one of three groups. One group received dimebon 20 mg three times a day (TID) one received 5 mg of dimebon TID, or one received a placebo TID for six months.
منابع مشابه
Dimebon and Alzheimer
Medivation has added Huntington’s Disease trials to its trials of Dimebon in Alzheimer’s Disease (AD). Following good results with a Phase II HD trial, a final phase III trial is now in the planning stages while a Phase III trial in AD is already underway. While the HD community awaits publication of all of the results in the newly ended Phase II trial, a newly published article in the Lancet i...
متن کاملDimebon alters hippocampal amyloid pathology in 3xTg-AD mice.
A double blind, placebo-controlled phase II study revealed that the antihistamine, Dimebon® (dimebolin, latrepirdine) improved cognition in Alzheimer disease (AD) patients compared to placebo controls. However, the Phase III CONNECTION trial failed to demonstrate significant differences between dimebon and placebo treatments. Despite the controversial therapeutic outcomes in the treatment of AD...
متن کاملThe reversal effect of mefenamic acid in the sporadic model of Alzheimer's disease in rat: a behavioral analysis
Alzheimer’s disease (AD) is a chronic neurodegenerative disease causing progressive impairment of memory and cognitive function. Streptozotocin (STZ) injection into the brain is known to cause cognitive impairment in rats and is similar to sporadic AD in humans. Several lines of evidence have indicated that an inflammatory process contributes to the pathology of AD. On the basis of the results ...
متن کاملThe reversal effect of mefenamic acid in the sporadic model of Alzheimer's disease in rat: a behavioral analysis
Alzheimer’s disease (AD) is a chronic neurodegenerative disease causing progressive impairment of memory and cognitive function. Streptozotocin (STZ) injection into the brain is known to cause cognitive impairment in rats and is similar to sporadic AD in humans. Several lines of evidence have indicated that an inflammatory process contributes to the pathology of AD. On the basis of the results ...
متن کاملThe beneficial effects of riluzole on GFAP and iNOS expression in intrahippocampal Aβ rat model of Alzheimer’s disease
Background and Objective: Alzheimer’s disease (AD) is a neurodegenerative disorder specified by deposition of b-amyloid (Ab) and neuronal loss that leads to learning and memory disturbances. One of the most important causes of AD is glutamate-dependent excitotoxicity in brain regions that is vulnerable to AD. According to previous reported results, it was revealed that riluzole, as a glutamate ...
متن کامل